

IAP20 Rec'd PCT/PTO 23 DEC 2005

Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	50318/011001
	Serial No.	10/562081
	Applicant	Olli Vuolteenaho et al.
	Filing Date	Not Yet Assigned
	Group	Not Yet Assigned
	IDS Filed	December 23, 2005

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	5,786,163	7/28/98	Hall			
	6,117,644	9/12/00	DeBold			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Misono et al., "Expression and Purification of the Extracellular Ligand-binding Domain of the Atrial Natriuretic Peptide (ANP) Receptor: Monovalent Binding with ANP Induces 2:2 Complexes," Biochem. 38:516-523, 1999.					
	Nishikimi et al., "Increased Plasma Levels of Adrenomedullin in Patients with Heart Failure," JACC 26:1424-1431, 1995.					
	Qi et al., "Natriuretic Peptides in Patients with Aortic Stenosis," American Heart Journal 142:725-732, 2001.					
	Ruskoaho, "Cardiac Hormones as Diagnostic Tools in Heart Failure," Endocr. Rev. 24:341-356, 2003.					
	Squire et al., "N-Terminal Pro-Atrial Natriuretic Peptide (N-ANP) and N-Terminal Pro-B-Type Natriuretic Peptide (N-BNP) in the Prediction of Death and Heart Failure in Unselected Patients Following Acute Myocardial Infarction," Clin. Sci. 107:309-316, 2004.					

EXAMINER /Shulamith Shafer/	DATE CONSIDERED 10/19/2008
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	